Synact Pharma Ab · OMXSTO:SYNACT
Synact Pharma Ab — Investor Presentation (February 2026)
27 slides from Synact Pharma Ab's investor presentation, February 2026
Slide 1: Company Presentation
Treating Inflammation through Resolution Therapy Company Presentation February 2026 Non-confidential
Slide 2: Forward Looking Statements
Forward Looking Statements Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except fo
Slide 3: Company in brief
Company in brief Resomelagon (AP 1189) Highlights PoC Phase 2 RESOVIR-1 Phase 2b ADVANCE Phase 2 RESOVIR-2 Phase 2 RESPIRE • Resomelagon: a novel approach in initiated in initiated in Dengue initiated in in Covid-19 patients Rheumatoid Arthritis respiratory viral autoimmune and inflammatory virus Po
Slide 4: Lead compound Resomelagon (Phase 2b)
Lead compound Resomelagon (Phase 2b) Reduces inflammatory activity and promotes resolution Potential first-in-class, non-suppressive Enables macrophage modulation Potential in multiple indications as a safe and effective add-on therapy
Slide 5: Resomelagon (AP1189) dual development strategy
Resomelagon (AP1189) dual development strategy Chronic Inflammation / Autoimmune Acute Inflammation Diseases impacted by highly pro-inflammatory monocytes and of site specific macrophages and neutrophils Unmet need: 18m diagnosed Safer treatments >2m hospitalized Unmet need: with Rheumatoid for infl
Slide 6: Chronic inflammation
Our compounds promotes resolution of inflammation The inflammatory response Excessive response Non-resolution Physiological immune response: Inflammatory response effectively controlled in extent and Chronic inflammation 1 time – protects tissues and limits damage Tissue damage 4 2 Pathways activate
Slide 7: Resomelagon MoA
Resomelagon MoA Novel biased melanocortin receptor agonists for MC1r Model MC3r Model M1/M2 macrophage modulation Simplified view of immune cell populations Exbibits anti-inflammatory activity via MC1r and MC3r stimulation on targets cells – such as lowering the release of pro-inflammatory cytokines
Slide 8: Development Programs
Development Programs COMPOUND INDICATION PRE-CLINICAL PHASE I PHASE IIa PHASE IIb STATUS & NEXT MILESTONE ADVANCE - Phase 2b study RESOMELAGON Rheumatoid Arthritis (RA) – recruitment completed RESPIRE - Phase 2 – Hyperinflammation due to Host-derived therapy in viral-infections RESOMELAGON respirato
Slide 9: Strong momentum on clinical trials enabling near term catalysts
Strong momentum on clinical trials enabling near term catalysts Clinical Study Near Term Business Execution Catalysts Development Resomelagon Ph2b study in ADVANCE study topline Strengthen business Rheumatoid Arthritis results informing Ph3 planning potential as ‘pipeline-in-a- (ADVANCE Study) (n=24
Slide 10: Rheumatoid Arthritis
Rheumatoid Arthritis Resomelagon –lead indication
Slide 11: Patient Journey in RA
Patient Journey in RA Treat-to-Target recommendations. Avoid damage to joints in the first 2–3 years2 Unclassified Arthritis Early RA Progressive RA Arthritis Referral to symptoms onset Rheumatologist Contraindication for Poor prognostic factors absent methotrexate Primary care Clinical diagnosis of
Slide 12: Rheumatoid Arthritis: Room for improvement in the treatment
Rheumatoid Arthritis Room for improvement in the treatment • More than 20% do not have any improvement in diseases activity following to the most aggressive treatment options, ie MTX +GC or Biologic treatment • 35-50% will not reach disease control on the most aggressive treatment options, ie MTX +G
Slide 13: Resomelagon BEGIN P2A Study
Resomelagon BEGIN P2A Study Demonstrated significant treatment effects in treatment naive RA patients Phase 2a double- blind placebo-controlled study 80% of had CRP higher than normal range and the in treatment naive RA patients with high disease majority of the patients were treated within weeks of
Slide 14: Resomelagon EXPAND study
Resomelagon EXPAND study * Significant treatment effect in subset of patients defined as newly diagnosed with sign of systemic inflammation Support continued development in RA BL CRP>3_ RA diagnose within 6 months from BL * * * *: p<0.023 vs placebo (Fischer exact test). Mean per group *:p<0.01 vs p
Slide 15: The EXPAND study: Safety profile
The EXPAND study Safety profile Arthritis Rheumatol. 2024; 76 (suppl 9)- ACR convergence 2024 abstract no 2274.
Slide 16: Resomelagon ADVANCE Study P2b
Resomelagon ADVANCE Study P2b Dose-range study in newly diagnoses treatment naive RA patients with high disease activity - Ongoing Patient Population: Intervention: Newly diagnosed treatment naïve RA pts, eligible Resomelagon (AP1189) 3 dose levels in for initiation of MTX treatment combination with
Slide 17: Host-directed therapy in viral infections
Host-directed therapy in viral infections Resomelagon
Slide 18: Patient Journey in Host Directed Viral Infections
Patient Journey in Host Directed Viral Infections Pre-hospital Hospitalization Symptoms of viral Inadequate infection pulmonary Antiviral Primary care function Pathogen Oxygen therapy Influenza Other (e.g. JAK) Covid-19 RSV ICU: est. 10-20%* Ventilation Potential: Resomelagon during hospital stay Ho
Slide 19: Host-directed therapy in viral infections (RESOVIR-1)
Host-directed therapy in viral infections (RESOVIR-1) Once a day tablet to induce pharmacological resolution The RESOVIR-1 study in pateints in need for supplementary oxygen therapy showed that resomelagon (AP1189) given once daily significantly reduced time to respiratory recovery,and reduced to ti
Slide 20: Host-directed therapy in viral infections RESPIRE study
Host-directed therapy in viral infections RESPIRE study Phase 2, randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of resomelagon in patients with respiratory insufficiency due to viral infection. Patient Population: Adults; including vulnerable patients Oral tablet;
Slide 21: Dengue Virus - Distribution and Incidence
Dengue Virus- Distribution and Incidence - Three-month dengue virus disease case notification rate per 100 000 population, January 2025-March 2025 According to the World Health Organization (WHO), dengue is now endemic in over 100 countries As many as 3.6 billion people, or 40% of the world's popula
Slide 22: The RESOVIR-2 study
The RESOVIR-2 study MauroTeixeira, MD, PhD Phase 2 proof of concept- initiated in Brazil- Professor of Immunology recruitment to be conducted and next epidemic at Universidade Federal de Minas Gerais (UFMG), Brazil site(s): Double-blind placebo controlled once daily dosing for 5 days. Treatment init
Slide 23: IP position
IP position
Slide 24: Multiple Layers of Protection
Multiple Layers of Protection CoM Crystal Form Asset in Development CoM Formulation US Patent 12,239,631 Composition of matter patent of the polymorphic form of the resomelagon salt currently employed in the clinic Use Resomelagon + MTX In RA Extends exclusivity until 2042 Patent application for a w
Slide 25: Leadership
Leadership
Slide 26: Dedicated and Experienced Top Management Team
Dedicated and Experienced Top Management Team Jeppe Øvlesen, MBA Thomas Jonassen, MD Malin Wikstrand Kirsten Harting, MD, Thomas Boesen, PhD Mads Bjerregaard, MSc CEO CSO, co-founder Interim CFO Executive MBA – CMO COO CBO Over 20 years of experience Associate Professor at Involved with SynAct Over
Slide 27: Very experienced Board of Directors
Very experienced Board of Directors Anders Kronborg Sten Scheibye Sten Sørensen Jeppe Ragner Andersen Chairman of the Board Board Member Board Member Board Member CEO or CFO, during 1996-2007 in Danish Started as medical sales rep, registration Over 30 years in the pharmaceutical Extensive financial
SynAct Pharma — Investor Presentation (February 2026) on 6ix